Ceapro Inc.

Equities

CZO

CA1499071076

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 13:07:46 2024-05-31 EDT			5-day change	1st Jan Change
0.225 ^CAD	-11.76%		-16.67%	+18.42%

05-29	Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	MT
05-29	Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Ceapro Inc. Announces Appointment of Geneviève Foster to Board of Directors

April 19, 2022 at 08:05 am

Ceapro Inc. announced the appointment of Geneviève Foster to its Board of Directors. Since 2008, Ms. Foster has run her own legal practice where she offers legal services to private SMEs and public companies, including companies in the pharmaceutical and life sciences industry.

Latest news about Ceapro Inc.

Ceapro's Q1 Net Loss Swells YoY, But Talks Up Benefits of Planned Aeterna Merger	05-29	MT
Ceapro Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-29	CI
Aeterna Zentaris Finalizes Some Details for Ceapro Merger	05-17	MT
Aeterna and Ceapro Brief: Aeterna Zentaris Announcing Details Regarding Transaction with Ceapro	05-17	MT
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Ceapro Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	04-29	CI
Ceapro Brief: Parties anticipate completing Transaction in Q2 2024, subject to obtaining all required approvals and satisfying all required conditions	03-28	MT
Ceapro Brief: Says Received Final Court Approval for Merger with Aeterna Zentaris	03-28	MT
Aeterna Zentaris Reports Q4 Net Loss of US$5.6 Million, Provides DETECT Trial Update	03-27	MT
Aeterna Zentaris Brief: Announcing Completion of Enrollment in Ongoing Pivotal DETECT-Trial for Diagnosis of Childhood-Onset Growth Hormone Deficiency	03-27	MT
Aeterna Zentaris Brief: Reporting Q4 Net Loss of US$5.6 million, or $1.16 loss per common share	03-27	MT
Ceapro Brief: Independent Proxy Advisory Firm ISS Recommends Aeterna Zentaris and Ceapro Securityholders Vote FOR Arrangement Agreement to Approve Merger of Equals to Create a Diversified Biopharmaceutical Co	02-26	MT
Aeterna Zentaris and Ceapro Announce Merger of Equals to Create Diversified Biopharmaceutical Co	12-14	MT
Aeterna Zentaris and Ceapro Brief: Cos Announcing Merger of Equals to Create a Diversified Biopharmaceutical Co	12-14	MT
Ceapro Inc. Announces Dosing of First Patients In Phase 1-2a Study of Avenanthramides	12-13	MT
Ceapro Inc. Announces Commencement of Patient Dosing in its Phase 1-2a Study Evaluating its Product, Avenanthramides, for Potential Applications in Managing Conditions Related to Inflammation	12-13	CI
Ceapro Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-29	CI
Ceapro Inc. Initiates Phase 1-2a Study Assessing Avenanthramides For Potential Applications in Inflammation Based Diseases	11-27	MT
Ceapro Inc. Initiates Phase 1-2A Study Assessing Its Product Avenanthramides for Potential Applications in Inflammation Based Diseases	11-27	CI
Ceapro Inc. entered into a definitive agreement to acquire Aeterna Zentaris Inc. for CAD 0.13 million in a merger of equals transaction.	11-08	CI
Ceapro Inc. Announces the Signing of A Technical Collaboration with NATEX Prozesstechnologie Gmbh to Accelerate the Scale-Up of Its Proprietary PGX Technology Towards Commercial Level	11-07	CI
Ceapro Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-29	CI
Ceapro Extends International Supply and Distribution Agreement with German Provider of Active Ingredients, Symrise	23-08-25	MT
Ceapro Inc. Extends Exclusive International Supply and Distribution Agreement with Symrise	23-08-25	CI
Ceapro Announces Next Phase of Research Collaboration with the Angiogenesis Foundation	23-07-18	MT

Chart Ceapro Inc.

Duration

Period

More charts

Company Profile

Ceapro Inc. is a Canada-based biotechnology company. The Company is involved in the development of extraction technology and the application of this technology to the production of extracts and active ingredients from oats and other renewable plant resources. Its primary business activities relate to the development and commercialization of natural products for personal care, cosmetic, human, and animal health industries using technology, natural, renewable resources, and developing products, technologies, and delivery systems. The Company's products include a commercial line of natural active ingredients, including beta glucan, avenanthramides (colloidal oat extract), oat powder, oat oil, oat peptides, and lupin peptides, a commercial line of natural anti-aging skincare products, utilizing active ingredients, including beta glucan and avenanthramides and veterinary therapeutic products, including an oat shampoo, an ear cleanser, and a dermal complex/conditioner.

Sector

Biotechnology & Medical Research

Calendar

2024-08-21 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
CEAPRO INC.	+18.42%	12.91M
MODERNA, INC.	+43.36%	54.64B
IQVIA HOLDINGS INC.	-5.31%	39.92B
LONZA GROUP AG	+37.52%	38.82B
ICON PUBLIC LIMITED COMPANY	+14.75%	26.86B
CELLTRION, INC.	-12.56%	26.22B
ALNYLAM PHARMACEUTICALS, INC.	-22.45%	18.78B
UNITED THERAPEUTICS CORPORATION	+25.12%	12.21B
BIO-TECHNE CORPORATION	+0.04%	12.16B
MEDPACE HOLDINGS, INC.	+26.04%	11.94B

Other Biotechnology & Medical Research